Safety and Immunogenicity of Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector) in Chinese Healthy Adults Aged 18-59 Years: a Randomized, Observer-blind, Parallel-controlled Clinical Trial
Latest Information Update: 06 Apr 2022
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 28 Mar 2022 Status changed from active, no longer recruiting to completed.
- 01 Feb 2022 Results published in the Nature Medicine
- 29 Jun 2021 Status changed from recruiting to active, no longer recruiting.